Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Status: | Available |
---|---|
Conditions: | Prostate Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 5/27/2013 |
Contact: | Astellas Pharma Global Development |
Email: | clintrials.info@us.astellas.com |
Phone: | 855-412-7865 |
A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor
its safety in patients with metastatic castration-resistant prostate cancer previously
treated with docetaxel-based chemotherapy.
THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) APPROVED MDV3100 (ENZALUTAMIDE) FOR
SALE TO THE PUBLIC, ENROLLMENT IS CLOSED IN THE UNITED STATES.
ENROLLMENT IS OPEN IN CANADA.
The expanded access treatment protocol is being conducted while marketing approval of
enzalutamide is being sought. There is no age requirement.
Subjects will complete visits on Day 1, Week 4, Week 12 and then every subsequent 12 weeks
until discontinued from the study.
The study will end if enzalutamide is approved for sale to the public by the country's
health authority (commercially available) or if the sponsor otherwise decides or is required
to end the study. If a subject would like to receive enzalutamide after the study ends, he
and the doctor will decide if he should receive a prescription for enzalutamide, with a goal
of avoiding any interruption in treatment.
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH)
analogue (agonist or antagonist) or orchiectomy
- At least one prior chemotherapy regimen for metastatic castration-resistant prostate
cancer with at least one regimen containing docetaxel
- Progressive disease as evidenced by prostate specific antigen (PSA) rise or
radiographic or clinical worsening of disease
- No known or suspected brain metastasis
- There is no comparable or satisfactory alternative therapy to treat the subject's
disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Exclusion Criteria:
- History of seizure or any condition that may predispose to seizure including, but not
limited to underlying brain injury, stroke, primary brain tumors, brain metastases,
or alcoholism
- History of loss of consciousness or transient ischemic attack within the last 12
months
- Clinically significant cardiovascular disease
- Following lab values:
- Absolute neutrophil count is <1,000/µL
- Platelet count is <50,000/µL
- Hemoglobin is < 5.6 mmol/L (9 g/dL)
- Total bilirubin ≥1.5 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≥2.5 x ULN
- Creatinine clearance is less than 30 ml/min by the Cockcroft and Gault formula
- Subject's conditions suggests that a bone fracture or complication of a bone fracture
(such as compression of the spinal cord or other nerves) is likely to occur very soon
- Subject has participated in a previous clinical study of MDV3100 for which the
primary endpoint has not yet been reported (e.g., the PREVAIL trial)
We found this trial at
36
sites
Click here to add this to my saved trials
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
823 82nd Parkway, Suite B
Myrtle Beach, South Carolina 29572
Myrtle Beach, South Carolina 29572
(843) 449-1010 ext.268
Carolina Urologic Research Center Carolina Urologic Research Center (CURC) has been recognized both nationally and...
Click here to add this to my saved trials
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Click here to add this to my saved trials
Cancer Care Centers of South Texas At Cancer Care Centers of South Texas, we are...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Tulsa Cancer Institute, Pllc Now under the new name of Tulsa Cancer Institute, our specialists...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials